Paolo Raggi1, Antonio Bellasi2, David Bushinsky3, Jordi Bover4, Mariano Rodriguez5, Markus Ketteler6, Smeeta Sinha7, Carolina Salcedo8, Kristen Gillotti9, Claire Padgett9, Rekha Garg9, Alex Gold9,10, Joan Perelló8,11, Glenn M Chertow10. 1. Department of Medicine, Mazankowski Alberta Heart Institute and University of Alberta, Edmonton, Canada (P.R.). 2. Research, Innovation and Brand Reputation Unit, ASST Papa Giovanni XXIII, Bergamo, Italy (A.B.). 3. Department of Medicine, University of Rochester Medical Center, NY (D.B.). 4. Department of Nephrology, Fundació Puigvert and Universitat Autònoma, IIB Sant Pau, REDinREN, Barcelona, Spain (J.B.). 5. Nephrology Unit, Hospital Universitario Reina Sofia, IMIBIC, REDinREN, Córdoba, Spain (M.R.). 6. Department of General Internal Medicine and Nephrology, Robert-Bosch-Krankenhaus, Stuttgart, Germany (M.K.). 7. Department of Renal Medicine, Salford Royal NHS Foundation Trust, UK (S.S.). 8. Research and Development, Sanifit Therapeutics, Palma, Spain (C.S., J.P.). 9. Research and Development, Sanifit Therapeutics, San Diego, CA (K.G., C.P. R.G., A.G.). 10. Department of Medicine, Stanford University, Palo Alto, CA (A.G., G.M.C.). 11. University of the Balearic Islands, Palma, Spain (J.P.).
Abstract
BACKGROUND: The high cardiovascular morbidity and mortality in patients with end-stage kidney disease could be partially caused by extensive cardiovascular calcification. SNF472, intravenous myo-inositol hexaphosphate, selectively inhibits the formation and growth of hydroxyapatite. METHODS: This double-blind, placebo-controlled phase 2b trial compared progression of coronary artery calcium volume score and other measurements of cardiovascular calcification by computed tomography scan during 52 weeks of treatment with SNF472 or placebo, in addition to standard therapy, in adult patients with end-stage kidney disease receiving hemodialysis. Patients were randomized 1:1:1 to SNF472 300 mg (n=92), SNF472 600 mg (n=91), or placebo (n=91) by infusion in the hemodialysis lines thrice weekly during hemodialysis sessions. The primary end point was change in log coronary artery calcium volume score from baseline to week 52. The primary efficacy analysis combined the SNF472 treatment groups and included all patients who received at least 1 dose of SNF472 or placebo and had an evaluable computed tomography scan after randomization. RESULTS: The mean change in coronary artery calcium volume score was 11% (95% CI, 7-15) for the combined SNF472 dose group and 20% (95% CI, 14-26) for the placebo group (P=0.016). SNF472 compared with placebo attenuated progression of calcium volume score in the aortic valve (14% [95% CI, 5-24] versus 98% [95% CI, 77-123]; P<0.001) but not in the thoracic aorta (23% [95% CI, 16-30] versus 28% [95% CI, 19-38]; P=0.40). Death occurred in 7 patients (4%) who received SNF472 and 5 patients (6%) who received placebo. At least 1 treatment-emergent adverse event occurred in 86%, 92%, and 87% of patients treated with SNF472 300 mg, SNF472 600 mg, and placebo, respectively. Most adverse events were mild. Adverse events resulted in discontinuation of SNF472 300 mg, SNF472 600 mg, and placebo for 14%, 29%, and 20% of patients, respectively. CONCLUSIONS: Compared with placebo, SNF472 significantly attenuated the progression of coronary artery calcium and aortic valve calcification in patients with end-stage kidney disease receiving hemodialysis in addition to standard care. Future studies are needed to determine the effects of SNF472 on cardiovascular events. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02966028.
RCT Entities:
BACKGROUND: The high cardiovascular morbidity and mortality in patients with end-stage kidney disease could be partially caused by extensive cardiovascular calcification. SNF472, intravenous myo-inositol hexaphosphate, selectively inhibits the formation and growth of hydroxyapatite. METHODS: This double-blind, placebo-controlled phase 2b trial compared progression of coronary artery calcium volume score and other measurements of cardiovascular calcification by computed tomography scan during 52 weeks of treatment with SNF472 or placebo, in addition to standard therapy, in adult patients with end-stage kidney disease receiving hemodialysis. Patients were randomized 1:1:1 to SNF472 300 mg (n=92), SNF472 600 mg (n=91), or placebo (n=91) by infusion in the hemodialysis lines thrice weekly during hemodialysis sessions. The primary end point was change in log coronary artery calcium volume score from baseline to week 52. The primary efficacy analysis combined the SNF472 treatment groups and included all patients who received at least 1 dose of SNF472 or placebo and had an evaluable computed tomography scan after randomization. RESULTS: The mean change in coronary artery calcium volume score was 11% (95% CI, 7-15) for the combined SNF472 dose group and 20% (95% CI, 14-26) for the placebo group (P=0.016). SNF472 compared with placebo attenuated progression of calcium volume score in the aortic valve (14% [95% CI, 5-24] versus 98% [95% CI, 77-123]; P<0.001) but not in the thoracic aorta (23% [95% CI, 16-30] versus 28% [95% CI, 19-38]; P=0.40). Death occurred in 7 patients (4%) who received SNF472 and 5 patients (6%) who received placebo. At least 1 treatment-emergent adverse event occurred in 86%, 92%, and 87% of patients treated with SNF472 300 mg, SNF472 600 mg, and placebo, respectively. Most adverse events were mild. Adverse events resulted in discontinuation of SNF472 300 mg, SNF472 600 mg, and placebo for 14%, 29%, and 20% of patients, respectively. CONCLUSIONS: Compared with placebo, SNF472 significantly attenuated the progression of coronary artery calcium and aortic valve calcification in patients with end-stage kidney disease receiving hemodialysis in addition to standard care. Future studies are needed to determine the effects of SNF472 on cardiovascular events. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02966028.
Authors: Joan Perelló; Miquel D Ferrer; Maria Del Mar Pérez; Nadine Kaesler; Vincent M Brandenburg; Geert J Behets; Patrick C D'Haese; Rekha Garg; Bernat Isern; Alex Gold; Myles Wolf; Carolina Salcedo Journal: Br J Pharmacol Date: 2020-08-23 Impact factor: 8.739
Authors: Zheng Qin; Ruoxi Liao; Yuqin Xiong; Luojia Jiang; Jiameng Li; Liya Wang; Mei Han; Si Sun; Jiwen Geng; Qinbo Yang; Zhuyun Zhang; Yupei Li; Heyue Du; Baihai Su Journal: Ann Transl Med Date: 2021-04
Authors: David A Bushinsky; Paolo Raggi; Jordi Bover; Markus Ketteler; Antonio Bellasi; Mariano Rodriguez; Smeeta Sinha; Rekha Garg; Joan Perelló; Alex Gold; Glenn M Chertow Journal: Clin J Am Soc Nephrol Date: 2021-04-07 Impact factor: 8.237
Authors: Miles D Witham; Jennifer S Lees; Myra White; Margaret Band; Samira Bell; Donna J Chantler; Ian Ford; Roberta L Fulton; Gwen Kennedy; Roberta C Littleford; Ian V McCrea; Deborah McGlynn; Maurizio Panarelli; Maximilian R Ralston; Elaine Rutherford; Alison Severn; Nicola Thomson; Jamie P Traynor; Allan D Struthers; Kirsty Wetherall; Patrick B Mark Journal: J Am Soc Nephrol Date: 2020-08-13 Impact factor: 10.121
Authors: Thijs T Jansz; Meike H Y Go; Nolan S Hartkamp; J Lauran Stöger; Csilla Celeng; Tim Leiner; Pim A de Jong; Frank J L Visseren; Marianne C Verhaar; Brigit C van Jaarsveld Journal: Kidney Med Date: 2021-04-20
Authors: Antonio Bellasi; Luca Di Lullo; Domenico Russo; Roberto Ciarcia; Michele Magnocavallo; Carlo Lavalle; Carlo Ratti; Mario Cozzolino; Biagio Raffaele Di Iorio Journal: Cells Date: 2021-05-03 Impact factor: 6.600